ATRECA, INC. INDEMNITY AGREEMENTIndemnity Agreement • May 24th, 2019 • Atreca, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into as of , between Atreca, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Herb CrossExecutive Employment Agreement • May 24th, 2019 • Atreca, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Herb Cross (the “Executive”) (collectively, the “Parties”), is effective as of February 1, 2019.
ATRECA, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTRights Agreement • May 24th, 2019 • Atreca, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of September 5, 2018, by and among Atreca, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
ATRECA, INC. WARRANT TO PURCHASE SERIES A PREFERRED STOCKAtreca, Inc. • May 24th, 2019 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, , or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from ATRECA, INC., a Delaware corporation, with its principal office at 500 Saginaw Dr., Redwood City, California 94063 (the “Company”) the Exercise Shares at the Exercise Price (each subject to adjustment as provided herein). This Warrant is being issued as one of a series of warrants (the “Warrants”) pursuant to that certain Placement Agency Agreement, dated March 25, 2015, by and between Brookline Group, LLC (“Brookline”) and the Company (the “Agreement”) in full satisfaction of the provisions of Section 3(e) thereof and pursuant to that certain Preferred Warrant Assignment Form, dated November 9, 2015, by and between Brookline and the Company (the “Assignment”). The aggregate number of Exercise Shares that Holder may purchase by exercising this warrant is shares of the Company’s Series A Preferred Stock (subject to adjustment pursuant
ATRECA, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for Tito SerafiniExecutive Employment Agreement • May 24th, 2019 • Atreca, Inc. • Pharmaceutical preparations • California
This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and Tito Serafini (the “Executive”) (collectively, the “Parties”), is effective as of date all parties have signed this Agreement (the “Effective Date”).
ATRECA, INC. EXECUTIVE EMPLOYMENT AGREEMENT for John OrwinExecutive Employment Agreement • May 24th, 2019 • Atreca, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”), made between Atreca, Inc. (the “Company”) and John Orwin (the “Executive”) (collectively, the “Parties”), is effective as of March 21, 2018 (“Effective Date”).
FIRST AMENDMENT TO SUBLEASE (500 SAGINAW DRIVE, REDWOOD CITY, CALIFORNIA)Sublease • May 24th, 2019 • Atreca, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is entered into as of August 25th, 2017 (as may be adjusted pursuant to Section 4, the “Effective Date”), by and between CARDIODX, INC., a Delaware corporation (“Sublandlord”), and ATRECA, INC., a Delaware corporation (“Subtenant”).
SUBLEASE (500 SAGINAW DRIVE, REDWOOD CITY, CALIFORNIA)Sublease • May 24th, 2019 • Atreca, Inc. • Pharmaceutical preparations • California
THIS SUBLEASE (this “Sublease”) is entered into as of March 22, 2016 (the “Effective Date”), by and between CARDIODX, INC., a Delaware corporation (“Sublandlord”), and ATRECA, INC., a Delaware corporation (“Subtenant”) (Sublandlord and Subtenant, each, a “Party”, and collectively, the “Parties”).
